Photo of Thomas A. WoottonPhoto of Thomas A. Wootton

Thomas A. Wootton

Partner

Education

University of California Hastings College of the Law, J.D.
University of California, B.S.

Prior Employment

  • Miller, Canfield, Paddock and Stone, P.L.C., Senior Counsel, 2007-2008
  • Pfizer, Senior Counsel, 1991-2007

Bar Admissions

Court Admissions

Professional Affiliations

American Bar Association

  • Intellectual Property Law Section
  • Litigation Section

State Bar of Michigan

State Bar of California

Kalamazoo County Bar Association

American Intellectual Property Law Association

Intellectual Property Owners Association

U.S. Patent and Trademark Office

Overview
Experience
News & Resources
Honors

Overview

Mr. Wootton counsels clients in the areas of chemical, biological and pharmaceutical patents, ideas and inventions.

  • Evaluates inventions and patents for his clients
  • Drafts and prosecutes patent applications 
  • Prepares, drafts and reviews patent and technology licensing agreements
  • Prepares oral and written opinions in various matters related to patents and trade secrets
  • Advise research team leaders concerning patents, products, trade secrets, trade mark and dress protection, and competitor positions
  • Perform related in-licensing evaluations, including due diligence, patentability and freedom-to-operate analysis

Experience

  • Represented both large human and animal health pharmaceutical companies and small start-up companies in their discovery and development of vaccines and adjuvants, methods of vaccinating vertebrates, growth promotants for animals, human taste masking and other formulations, and human skin care products as well as peptide and organic molecule insecticides, their manufacture and formulations thereof
  • Prosecuted over 100 patents to allowance for Pfizer and its legacy companies, Pharmacia and the Upjohn Company   
  • Prepared patent applications for a variety of organic compounds, including heterocyclics,  quinolones, taxols, steroids, lipophilic polyamines, organic crystals, quinolones, taxols, steroids, lipophilic polyamines, azidophenylcyanoguanidines, organic crystals 
  • Prepared patent applications for a variety of biological subjects, including: polynucleic acids, polypeptides, proteins, oligosaccharides, bacteria and viral products and related cellular components, phage display, vaccines, antibodies, adjuvants, formulations and biological crystal
  • Representative sample of issued patents prepared and/or prosecuted:
    • US 7,232,680 B2, Jun. 19, 2007. Infectious CDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof. Calvert et al.
    • US 7,132,106 B2, Nov. 7, 2006. Infectious CDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof. Calvert et al.
    • US 7,041,473 B1, May 9, 2006. Alzheimer’s disease secretase, APP substrates therefor, and uses thereof. Gurney et al.
    • US 6,913,918 B2, Jul. 5, 2005. Alzheimer’s disease secretase, APP substrates therefor, and uses therefor. Gurney et al.
    • US 6,869,965 B2, Mar. 22, 2005. Antimicrobial quinolone derivatives and use of the same to treat bacterial infections. Gordeev et al.
    • US 6,867,018 B1, Mar. 15, 2005. Alzheimer’s disease secretase, APP substrates therefor, and uses thereof. Gurney et al.
    • US 6,846,640 B2, Jan. 25, 2005. Time-resolved fluorescence assay for the detection ofmultimeric forms of A-Beta 1-40. Peach et al.
    • US 6,844,148 B1, Jan. 18, 2005. Alzheimer’s disease secretase, APP substrates therefor, and uses therefor. Gurney et al. US 6,841,557 B2, Jan. 11, 2005. Compounds for the treatment of addictive disorders. Anderson et al.
    • US 6,835,565 B1, Dec. 28, 2004. Alzheimer’s disease secretase. Gurney et al.
    • US 6,828,117 B2, Dec. 7, 2004. Alzheimer’s disease secretase, APP substrates therefor, and uses therefor. Gurney et al.
    • US 6,825,023 B1, Nov. 30, 2004. Alzheimer’s disease secretase, APP substrates therefor, and uses therefor. Gurney et al.
    • US 6,797,487 B2, Sep. 28, 2004. Polynucleotides encoding Alzheimer’s disease secretase. Gurney et al.
    • US 6,790,610 B2, Sep. 14, 2004. Alzheimer’s disease, secretase, APP substrates therefor, and uses therefor. Gurney et al.
    • US 6,689,769 B2, Feb. 10, 2004. Antimicrobial quinolone derivatives and use of the same to treat bacterial infections. Gordeev et al.
    • US 6,458,820 B1, Oct. 1, 2002. Method for preventing or the progression of neuronal damage with pramipexole as a neuroprotective agent. Hall et al.
    • US 6,440,694 B1, Aug. 27, 2002. TNF-related death ligand. Bienkowski et al.
    • US 6,410,597 B2, Jun. 25, 2002. Use of pramipexole for the treatment of addictive disorders. Marshall et al.
    • US 6,391,876 B1, May 21, 2002. Reboxetine for treatment obsessive compulsive disorders and panic disorder. Dubini et al.

Honors

  • The Best Lawyers in America, 2010-2017